GCN2iB is a novel, potent and ATP-competitive inhibitor of a serine/threonine-protein kinase general control nonderepressible 2 (GCN2) with an IC50 of 2.4 nM. GCN2iB has the potential to be used for the treatment of cancer. The inhibition of GCN2 sensitizes cancer cells with low basal-level expression of asparagine synthetase (ASNS) to the antileukemic agent L-asparaginase (ASNase) in vitro and in vivo.

纯度：≥98%

CAS：2183470-12-2